Nature publication describes first example of a clinically applicable and systemic mRNA cancer immunotherapy vaccine Read more about Nature publication describes first example of a clinically applicable and systemic mRNA cancer immunotherapy vaccine
BioNTech to enter into worldwide strategic collaboration with Genentech to develop individualized mRNA cancer therapies Read more about BioNTech to enter into worldwide strategic collaboration with Genentech to develop individualized mRNA cancer therapies
Nature Medicine Reports Elimination of large Tumors in Mice by mRNA-encoded Bispecific Antibodies Read more about Nature Medicine Reports Elimination of large Tumors in Mice by mRNA-encoded Bispecific Antibodies
Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME Read more about Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
BioNTech Secures USD 270 Million in Series A Financing Read more about BioNTech Secures USD 270 Million in Series A Financing
BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer Read more about BioNTech Appoints Dr. Özlem Türeci as Chief Medical Officer
BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases Read more about BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza Read more about BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases Read more about BioNTech and the University of Pennsylvania Enter into Strategic Research Collaboration to Develop mRNA Vaccine Candidates Against Various Infectious Diseases
Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors Read more about Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors
